Targeting the TRPV1 pain pathway in osteoarthritis of the knee
Ali Mobasheri,François Rannou,Stefan Ivanavicius,Philip G. Conaghan
DOI: https://doi.org/10.1080/14728222.2024.2416961
IF: 6.797
2024-10-27
Expert Opinion on Therapeutic Targets
Abstract:Introduction The growing prevalence and lack of effective pain therapies for knee osteoarthritis (KOA) results in a substantial unmet need for novel analgesic therapies. The transient receptor potential vanilloid 1 (TRPV1) receptor is expressed in subsets of nociceptive sensory neurons and has major roles in pain transmission and regulation. In the structures of the knee joint, nociceptors are present in abundance.
pharmacology & pharmacy
What problem does this paper attempt to address?